First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer

Summary

Phase II, single-arm study to assess the safety and efficacy of osimertinib (80 mg, orally, once daily) as first-line therapy in patients with EGFR mutation-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously treated with an epidermal growth factor tyrosine kinase inhibitor agent.

Timeline

Start

2018-12-01

Primary completion

2025-06-01

Completion

2025-12-31

Drugs

Indications